Drugs / Urotol®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03575702 Comparator | Jul 2016 → Aug 2017 | overactive bladder | R-Pharm | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Urotol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03575702 ↗ |
| Action | Inhibit | “m-cholinergic antagonists group Urotol® (Tolterodine)” NCT03575702 ↗ |